# Mirror Biologics, Inc.

> Mirror Biologics is a clinical-stage, international biopharmaceutical company developing an 'off-the-shelf' class of immunotherapy built on living, non-genetically-manipulated immune cells. Its patented Mirror Effect platform - protected by more than 200 issued patents - powers a pipeline led by AlloStim for cancer, AlloPrime as a universal anti-viral vaccine for the elderly, and StimVax as a neoantigen vaccine. Headquartered in Tampa, Florida with GMP manufacturing in Jerusalem and clinical operations across Thailand and Malaysia, the company is advancing AlloStim into late-stage trials, including a Phase II metastatic colorectal cancer study run in collaboration with Merck KGaA.

- **Founded:** 2018
- **Headquarters:** Tampa, Florida, United States
- **Founders:** Michael Har-Noy (Founder & Chief Medical Officer (former CEO))
- **Team size:** ~16 employees
- **Products:** AlloStim, AlloPrime, StimVax, Mirror Effect Platform
- **Notable:** Built a Mirror Effect platform protected by more than 200 issued patents worldwide, Advanced AlloStim into late-stage clinical development, including a Phase IIB metastatic colorectal cancer trial, Secured a clinical collaboration and avelumab supply agreement with Merck KGaA (2025)

## Products & services

- **AlloStim** — Lead product candidate: an off-the-shelf, non-genetically-manipulated, disease-agnostic living immune cell derived from precursors purified from healthy-donor blood and expanded in 'artificial lymph node' bioreactors. In late-stage clinical development for cancers including metastatic colorectal cancer.
- **AlloPrime** — A universal anti-respiratory-viral vaccine using AlloStim cells to restore cellular immunity in the elderly, aiming to protect against COVID variants, influenza and RSV. Completed a Phase I/II trial in adults over 65.
- **StimVax** — An immunomodulatory neoantigen vaccine combining endogenous heat-shock proteins released from tumor or virus-infected cells lysed by activated immune cells, combined with AlloStim.
- **Mirror Effect Platform** — The underlying technology that reverse-engineers effective immune cascades while excluding associated toxicities; protected by over 200 issued patents worldwide.

## Achievements

- Built a Mirror Effect platform protected by more than 200 issued patents worldwide
- Advanced AlloStim into late-stage clinical development, including a Phase IIB metastatic colorectal cancer trial
- Secured a clinical collaboration and avelumab supply agreement with Merck KGaA (2025)
- Completed a Phase I/II AlloPrime trial in adults over 65 and published results indicating reversal of immunosenescence (2025)
- Received Israel Ministry of Health clearance for a new GMP manufacturing facility design in Jerusalem
- Closed the final $20M tranche of a $30M Series A with Bradbury Asset Management (2024)

## Latest updates

- **2025-01** — Entered a clinical collaboration and supply agreement with Merck KGaA to test AlloStim plus avelumab in metastatic colorectal cancer.
- **2025-05** — Published Phase I/II AlloPrime results suggesting allo-priming can reverse immunosenescence in adults over 65.
- **2024-04** — Appointed Elizabeth Czerepak as CFO and VP Corporate Development and closed the final $20M tranche of its $30M Series A.

## Links

- Website: https://mirrorbio.com
- LinkedIn: https://www.linkedin.com/company/mirror-biologics-inc

---

Profile page: https://yespress.io/mirror-biologics-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-18